BHVN

12.3909.23%
BD

Bruce D. Car

Chief Innovation Officer

Dr. Bruce D. Car, DVM, MVS, PhD, DACVP, is Chief Innovation Officer of Biohaven Pharmaceutical Holding Company Ltd. from August 2026. He has been the Chief Scientific Officer at Bexorg, Inc. since July 2026. He serves as Chief Innovation Officer at Biohaven Ltd. since July 13, 2026. He served as Chief Scientific Officer at Biohaven Ltd. since August 01, 2022 until July 13, 2026 and served as its Chief Innovation Officer since July 13, 2026 until 2026. He was Chief Scientific Officer of Biohaven Pharmaceutical Holding Company Ltd. Having served since January 2020 and Chief Scientific Officer at Agios Pharmaceuticals, where the research focus was initially oncology and genetically defined diseases (GDD), later driving the portfolio to sole GDD approaches. Prior to Agios, he spent many years at Bristol-Myers Squibb (BMS) and its legacy companies, working across all therapeutic areas and drug modalities. For more than two decades, he held roles of increasing responsibility in drug discovery, covering all therapeutic areas, drug platforms, India R&D site and different stages of discovery. In early 2017, he became the first head of the BMS Translational Medicine function, where he built a cohesive team of over 300 scientists and specialists covering biomarkers through data science and pharmaco-diagnostics. During his tenure with BMS, Dr. Car contributed to progressing approximately 250 internally discovered drug candidates and over 18 drug registrations. Dr. Car held leadership positions spanning drug discovery covering all therapeutic areas, drug platforms, including the first head of BMS Translational Medicine team. Dr. Car left BMS as the interim head of Drug Discovery. Dr. Car received a degree in Veterinary Medicine from The University of Melbourne, Victoria, Australia (’83) and his Ph.D (’89) from Cornell University, NY, USA. He holds specialty certifications in anatomic and clinical pathology. Dr. Car undertook his postdoctoral studies in immunology and inflammation at the Theodor Kocher Institute, University of Berne and ETH/University of Zurich in Switzerland.

Positions